[Editorial] New guidelines for idiopathic pulmonary fibrosis
International experts in idiopathic pulmonary fibrosis (IPF) have issued new treatment guidelines to reflect the advances made recently in this terminal disease. Survival for people with IPF—a chronic, progressive, fibrosing form of interstitial pneumonia—was historically around 50% at 3 years. Treatment options have centred on best supportive care including oxygen and pulmonary rehabilitation. Pharmacological disease-modifying interventions have been disappointing. Combination therapy with prednisone, azathioprine, and N-acetylcysteine showed promise, but the results of the PANTHER-IPF study showed an excess of deaths and serious adverse events without evidence of benefit.